Log In
Print
BCIQ
Print
Print this Print this
 

OTX015, Y-803

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionSynthetic small molecule inhibitor of BET bromodomain containing 2 (BRD2), BRD3 and BRD4
Molecular Target Bromodomain containing 2 (BRD2) ; Bromodomain containing 3 (BRD3)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies
Regulatory Designation

Partner

Oncoethix S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today